Antibody-Drug Conjugates and Immune Checkpoint Inhibitors in Cancer Treatment

Antibody-drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) represent two major advances in the field of cancer immunotherapy. While both approaches have achieved notable successes, especially in targeting specific cancers, their individual limitations, such as restricted efficacy in certain tumor types and adverse side effects, present challenges. Combining these two therapies has emerged as a promising strategy to address these shortcomings.  

Efficacy of ADC and ICI Combination Therapy 

In a review by Zhang et al., a meta-analysis shows the promising potential of combining ADCs and ICIs, particularly in lymphomas, where standard therapies may have limited success.¹ The ability of ADCs to precisely target tumor cells and deliver cytotoxic drugs, combined with the immune-stimulating effects of ICIs, creates a robust dual-approach to tumor eradication. 

Although the combination of ADCs and ICIs shows encouraging efficacy, it is not without safety concerns. The most frequently reported adverse event (AE) was peripheral neuropathy, affecting 38% of patients. Additionally, toxicities affecting the skin and digestive system were observed in 13.1%–20% and 9%–36% of patients, respectively. These side effects highlight the need for ongoing research into strategies to mitigate these toxicities and enhance the safety profile of combination therapy. 

The data underscores the importance of managing treatment-related toxicities, particularly in the skin and digestive systems, to improve patient outcomes and ensure long-term tolerability. As ADCs and ICIs continue to be integrated into the treatment landscape, attention to adverse event management will be crucial in optimizing their clinical application. 

Mechanisms of Synergy: ADCs and ICIs 

The rationale for combining ADCs and ICIs is due to their complementary mechanisms of action. ADCs target specific antigens on cancer cells, delivering cytotoxic payloads directly to the tumor. This precision minimizes systemic exposure, reducing damage to healthy tissue. On the other hand, ICIs unleash the body's immune response by inhibiting checkpoints that cancer cells exploit to evade immune detection. 

Research suggests that specific payloads in ADCs can activate dendritic cells and promote T-cell infiltration into tumors. This effect enhances the immune system’s response to ICIs, making the cancer cells more susceptible to immune-mediated destruction. Furthermore, ADCs can induce immunogenic cell death, triggering both innate and adaptive immune responses, which amplifies the anti-tumor effect. This dual mechanism not only increases the efficacy of treatment but also helps overcome challenges like drug resistance that can limit the effectiveness of monotherapy. 

Overcoming Challenges in ADC and ICI Therapy 

The development of drug resistance, off-target toxicity, and variability in patient response continue to be significant barriers to achieving optimal outcomes. Future research should focus on overcoming these hurdles through the development of more sophisticated ADC designs, improved ICI targeting, and better management of immune-related adverse events (irAEs). Moreover, ongoing efforts to refine the pharmacokinetics of ADCs—such as optimizing the linker chemistry to ensure controlled drug release at the tumor site—will be needed in reducing off-target effects and improving therapeutic efficacy. As more is learned about the tumor microenvironment and its interaction with immune therapies, the ability to design more precise combination therapies will likely improve. 

Biointron’s catalog products for in vivo research can be found at Abinvivo, where we have a wide range of Antibody-Drug Conjugates, Benchmark Positive Antibodies, Isotype Negative Antibodies, Anti-Mouse Antibodies, and Bispecific Antibodies. Contact us to find out more at info@biointron.com or +86 400-828-8830 / +1(732)790-8340.

References:

1. Zhang, L., Yan, Y., Gao, Y., Chen, Y., Yu, J., Ren, N., & Sun, L. (2024). Antibody–drug conjugates and immune checkpoint inhibitors in cancer treatment: A systematic review and meta-analysis. Scientific Reports, 14(1), 1-11. https://doi.org/10.1038/s41598-024-68311-z